Search Results
Updates from DESTINY-Gastric 01
Dr. Janjigian on Updated Results from the DESTINY-Gastric01 Trial in HER2+ Gastric Cancer
Analyzing the DESTINY-Gastric01 Trial for Gastric or GEJ Adenocarcinoma
TOP TALK (EP 1) - Explore the "causes & effects" of DESTINY-Gastric01 in the field of gastric cancer
HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents
Updated analysis of DESTINY-Gastric02: T-DXd in HER2+ GEJ cancer who progressed with trastuzumab
Updates in the Management of Metastatic Gastroesophageal Cancer | Saurin Chokshi, MD
Practice-Changing Updates in the First-Line Treatment of Gastric/GEJ Cancer (1 of 2)
DESTINY-Gastric02: T-Dxd as a second-line treatment for HER2-positive gastric cancer
Gastric Cancer Updates
Latest news in gastric cancer from ASCO GI
Antibody Drug Conjugates for Gastric Cancer
